Clinical Trial

A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label, multicenter Phase II study of MHB036C combined with MHB039A in patients with advanced Breast Cancer or other advanced malignant solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of MHB036C and MHB039A combination therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-12.
Status change: Not Yet Recruiting → Recruiting 2025-11-16
Trial Details
NCT Number NCT07130383
Lead Sponsor Minghui Pharmaceutical (Hangzhou) Ltd
Conditions Advanced Breast Cancer, Advanced Malignant Solid Tumor
Enrollment 210 participants
Start Date 2025-09-30
Primary Completion 2029-08 (estimated)
Study Completion 2031-08 (estimated)
Updated on ClinicalTrials.gov 2025-11-18